Polymyalgia rheumatica (PMR) is diagnosed through a combination of symptoms, blood tests, and sometimes imaging, rather than any single definitive test. There is no specific antibody or biomarker unique to PMR, so doctors rely on a pattern of clinical findings, elevated inflammation markers, and a characteristic rapid response to low-dose steroids to confirm the diagnosis.
Who Gets Evaluated for PMR
PMR almost exclusively affects people over 50, and incidence rates climb steadily with age until about 80. It’s most common in White adults, with an annual incidence of roughly 58 to 96 per 100,000 people in that age group. If you’re under 50 and experiencing similar symptoms, your doctor will likely explore other conditions first, since age 50 or older is a mandatory starting criterion in the classification guidelines used internationally.
The Symptoms Doctors Look For
The hallmark of PMR is new-onset bilateral shoulder pain, meaning both shoulders ache. This was selected as the core entry criterion in the 2012 classification guidelines developed jointly by European and American rheumatology organizations. Hip pain or limited hip movement is also common and adds to the diagnostic picture.
Morning stiffness is another key feature. Depending on which set of criteria your doctor uses, stiffness lasting more than 45 minutes to an hour after waking supports a PMR diagnosis. This isn’t ordinary stiffness from sleeping in a bad position. It’s a deep, persistent aching and tightness in the shoulders, upper arms, neck, and hips that makes getting out of bed and raising your arms genuinely difficult. The stiffness typically improves as the day goes on but returns the next morning.
Importantly, PMR tends not to cause pain in smaller peripheral joints like the hands, wrists, or feet. If those joints are prominently involved, your doctor may suspect rheumatoid arthritis instead.
Blood Tests and Inflammation Markers
Two blood tests form the backbone of the lab workup: the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Both measure general inflammation in the body. In PMR, ESR values of 40 mm/h or higher and CRP levels above 6 mg/l are considered diagnostically significant thresholds, first proposed in the late 1970s and early 1980s and still used today.
However, elevated ESR and CRP are not unique to PMR. They rise in infections, cancers, and many other inflammatory conditions. That’s why these markers support the diagnosis rather than confirm it on their own. It’s also worth knowing that a small number of people with genuine PMR present with normal ESR and CRP at the time of diagnosis, so normal results don’t automatically rule it out if the rest of the clinical picture fits.
Your doctor will also check for rheumatoid factor (RF) and anti-CCP antibodies. These tests aren’t used to confirm PMR. They’re used to rule out late-onset rheumatoid arthritis, which can look remarkably similar. RF is positive in roughly 67% of late-onset rheumatoid arthritis patients but only about 7% of people with PMR. Anti-CCP antibodies serve a similar distinguishing role with good sensitivity and specificity. In the 2012 scoring system, the absence of both RF and anti-CCP adds two points toward a PMR classification.
How the Scoring System Works
The 2012 provisional classification criteria use a point-based scoring algorithm. You must first meet the entry requirements: age 50 or older, new bilateral shoulder pain, and abnormal CRP or ESR. From there, points are assigned:
- Morning stiffness lasting more than 45 minutes: 2 points
- Hip pain or limited hip range of motion: 1 point
- Negative RF and/or anti-CCP antibodies: 2 points
- Absence of other peripheral joint pain: 1 point
A score of 4 or higher classifies the case as PMR. This threshold has about 68% sensitivity and 78% specificity, meaning it correctly identifies most PMR cases while excluding most non-PMR conditions. These numbers reflect the inherent difficulty of diagnosing a condition with no disease-specific marker. In practice, doctors use the scoring system as a framework alongside their clinical judgment rather than as a rigid checklist.
The Steroid Response Test
One of the most distinctive features of PMR is how dramatically and quickly it responds to a low dose of corticosteroids. A starting dose of 15 to 20 mg per day of prednisone typically produces near-complete symptom resolution within 48 to 96 hours, along with normalization of inflammation markers. This rapid response has been recognized as a diagnostic feature of PMR since the 1980s.
If you start low-dose prednisone and feel dramatically better within a few days, that strongly supports the diagnosis. If the response is incomplete or takes much longer, your doctor may reconsider whether something else is going on, including giant cell arteritis or late-onset rheumatoid arthritis (which also responds to steroids, but typically requires higher doses).
When Imaging Helps
Ultrasound is sometimes used to strengthen a PMR diagnosis, particularly when the clinical picture is ambiguous. Typical ultrasound findings in the shoulders include inflammation of the subdeltoid bursa (a fluid-filled cushion near the shoulder joint) and swelling around the biceps tendon. In the hips, ultrasound often reveals joint inflammation and bursitis around the outer hip.
Imaging isn’t required for diagnosis in most cases, but it can help distinguish PMR from other causes of shoulder and hip pain, especially in patients whose blood work is borderline or who have features that overlap with rheumatoid arthritis. More severe, proliferative inflammation of the shoulder bursae on imaging tends to point toward rheumatoid arthritis rather than PMR.
Screening for Giant Cell Arteritis
About 10% of people initially diagnosed with “isolated” PMR go on to develop symptoms of giant cell arteritis (GCA), a related condition involving inflammation of blood vessels, particularly around the temples. Conversely, 17% to 66% of GCA patients also have PMR symptoms. Because of this overlap, your doctor will watch for warning signs of GCA during the diagnostic process and throughout treatment.
Red flags that prompt further investigation include new headaches, jaw pain when chewing, scalp tenderness, vision changes, severe anemia, or high platelet counts. A poor response to low-dose prednisone or persistently elevated inflammation markers also raises suspicion for underlying GCA. In those cases, ultrasound of the temporal arteries or a temporal artery biopsy may be performed. Patients under 70 without any of these cranial symptoms are unlikely to have a positive biopsy, so the additional testing is typically reserved for those with suggestive features.
Why Diagnosis Takes Clinical Judgment
The biggest challenge with PMR diagnosis is that no single test can confirm it. There’s no PMR-specific antibody, no imaging finding that’s unique to the condition, and the blood markers it relies on are shared with dozens of other diseases. Diagnosis is ultimately a process of matching the right pattern of symptoms, lab results, and treatment response while systematically ruling out conditions that mimic it, particularly late-onset rheumatoid arthritis, GCA, infections, thyroid disease, and certain cancers.
This is why many people with PMR see their doctor several times before receiving a definitive diagnosis. If your symptoms fit the pattern but your initial workup is inconclusive, a trial of low-dose prednisone and a follow-up visit to assess your response is often the most informative next step.